An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe

Pharmacogenetics and Genomics

Volumn 20, Issue 5, 2010, Pages 307-314

  Orkin, Chloe ^a   Wang, Jianmin ^b   Bergin, Colm ^c   Molina, Jean Michel ^d   Lazzarin, Adriano ^e   Cavassini, Matthias ^f   Esser, Stefan ^g   Gómez Sirvent, Juan Luis ^h   Pearce, Helen ⁱ  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b RTI HEALTH SOLUTIONS   (United States)

^c ST JAMES S HOSPITAL   (Ireland)

^d SAINT LOUIS HOSPITAL   (France)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

ⁱ GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Abacavir; Histocompatibility complex class I; HLA B 5701; Hypersensitivity; Pretreatment screening; Prevalence

Indexed keywords

HLA B ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; ETHNICITY; EUROPE; GENE FREQUENCY; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77951621770     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283390666     Document Type: Article

References (35)

1. Cutrell AG, Hernandez JE, Fleming JW, Edwards MT, Moore MA, Brothers CH, et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother 2004; 38:2171-2172.
2. Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23:1603-1614. (Pubitemid 33063588)
3. Peyriere H, Guillemin V, Lotthe A, Baillat V, Fabre J, Favier C, et al. Reasons for early abacavir discontinuation in HIV-infected patients. Ann Pharmacother 2003; 37:1392-1397. (Pubitemid 37205492)
4. Rauch A, Nolan D, Thurnheer C, Fux CA, Cavassini M, Chave JP, et al. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. Antivir Ther 2008; 13:1019-1028.
5. Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, Lai EH, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004; 5:203-211. (Pubitemid 38351278)
6. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727-732. (Pubitemid 34215071)
7. Phillips EJ, Wong GA, Kaul R, Shahabi K, Nolan DA, Knowles SR, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 2005; 19:979-981. (Pubitemid 40834943)
8. Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004; 101:4180-4185. (Pubitemid 38405903)
9. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568-579.
10. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006; 43:99-102. (Pubitemid 43939082)
11. Reeves I, Churchill D, Fisher M. Prospective genetic screening decreases the incidence of abacavir hypersensitivity [abstract]. Antivir Ther 2006; 11 (Suppl 3):S1-S192.
12. Zucman D, Truchis P, Majerholc C, Stegman S, Caillat-Zucman S. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 2007; 45:1-3. (Pubitemid 46684436)
13. European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV infected adults in Europe. Available at: http://www.europeanaidsclinicalsociety.org/guidelinespdf/1-Treatment-of-HIV- Infected-Adults.pdf. [Accessed June 2009]
14. Gazzard BG. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9:563-608.
15. European Medicines Agency. Ziagen (abacavir sulfate) summary of product characteristics. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ Ziagen/H-252-PI-en.pdf. [Accessed: June 2009]
16. Ziagen (abacavir sulfate) prescribing information. USA. Available at: http://us.gsk.com/products/assets/us-ziagen.pdf. [Accessed July 2009]
17. Ziagen (Abacavir sulfate) product monograph. Canada. Available at: http://www.gsk.ca/english/docs-pdf/Ziagen-PM-2008-10-09.pdf. [Accessed July 2009]
18. Orkin C, Sadiq T, Jackson F, Rice L, McCaughney, Tariq S, et al. Prospective epidemiological study of the prevalence of HLA-B*5701 in HIV-1-infected UK subjects. Presented at: 11th European AIDS conference; 2007; Madrid. Poster 4.4/02.
19. Molina JM, Pialoux G, Raffi F, Force G, Girard PM, Verdon R, et al. A prospective epidemiological study to determine the prevalence of HLA-B*5701 in French HIV-1-infected patients: PEPI study. Presented at: 11th European AIDS conference; 2007; Madrid. Poster 18.1/01.
20. Prins JM, Bergin C, Ristola M, Branco T, Rauch A, Pearce H, et al. CNA110329; prospective epidemiological study to determine the prevalence of HLA-B*5701 in HIV-1 infected individuals in 5 European countries (EPI study). Presented at: 9th International Congress on Drug Therapy in HIV Infection; 2008; Glasgow.
21. Esser S, van Lunzen J, Bausewig M, Thiele B, Mosmang M, Banjik N, et al. Phenotype frequency of HLA-B*5701 in HIV-infected patients in Germany. Kongressfur Infektions-und Tropenerkrankungen; 2008; Innsbruck. Poster 219.
22. Arrizabalaga J, Rodriguez-Alcantara F, Castaner JL, Ocampo A, Podzamczer D, Pulido F, et al. Prevalence of HLA-B*5701 in HIV-infected patients in Spain (results of the EPI Study). HIV Clin Trials 2009; 10:48-51.
23. Orkin C, Sadiq S, Rice L, Jackson F. Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B5701 in HIV-1-infected UK subjects. HIV Med 2010; 11:187-192.
24. Joint United Nations Programme on HIV/AIDS (UNAIDS/WHO) 2008; Report on the global AIDS epidemic. 2008. Available at: http://www.unaids.org/en/ KnowledgeCentre/HIVData/Epidemiology/latestEpiData.asp. [Accessed October 2008]
25. EuroHIV. HIV/AIDS Surveillance in Europe. End-year report 2006. Saint-Maurice: Institut de veille sanitaire, 2007. No.75.
26. EuroHIV. HIV/AIDS Surveillance in Europe. End-year report 2005. Saint-Maurice: Institut de veille sanitaire, 2006. No.73.
27. EuroHIV. HIV/AIDS Surveillance in Europe. End-year report 2004. Saint-Maurice: Institut de veille sanitaire, 2005. No.71.
28. EuroHIV. HIV/AIDS Surveillance in Europe. End-year report 2003. Saint-Maurice: Institut de veille sanitaire, 2004. No.70.
29. Instituto de Salud Carlos III and Ministerio de Sanidad y Consumo. Hospital survey of HIV/AIDS patients. Results 2004. Analysis of the evolution 1996-2004 (Spain), 2005. Available at: http://www.iscii.es/htdocs/pdf/hospital- survey.pdf. [Accessed March 2009]
30. Camoni L, Salfa MC, Regine V, Pasqualini C, Borghi V, Icardi G, et al. HIV incidence estimate among non-nationals in Italy. Eur J Epidemiol 2007; 22:813-817. (Pubitemid 350105370)
31. Health Protection Agency. Survey of Prevalent HIV Infections Diagnosed (SOPHID), data tables 2007. Available at: http://www.hpa.org.uk/web/HPAwebFile/ HPAweb-C/1221482342683. [Accessed June 2009]
32. Van Sighem A. HIV Monitoring Foundation Scientific Report 2007; Baselines and Trends (page 72, table 4.1). Available at: http://www.hiv-monitoring.nl/- site1134/images/SR-2007-4- Baselines-and-trends.pdf. [Accessed June 2009]
33. Hammond E, Almeida CA, Mamotte C, Nolan D, Phillips E, Schollaardt TA, et al. External quality assessment of HLA-B*5701 reporting: an international multicentre survey. Antivir Ther 2007; 12:1027-1032. (Pubitemid 350114982)
34. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004; 14:335-342. (Pubitemid 38813687)
35. Wolf E, Stoll M, Becker-Andre M, Bognor J, Becker W, Gorriahn D, et al. Prospective HLA-B*5701 screening for abacavir hypersensitivity saves costs. Presented at: XVII International AIDS conference; 2008; Mexico City. Poster THPE 0192.